The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; Chief ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...